[Code of Federal Regulations]
[Title 9, Volume 1]
[Revised as of January 1, 2001]
From the U.S. Government Printing Office via GPO Access
[CITE: 9CFR113.34]

[Page 568-569]
 
                  TITLE 9--ANIMALS AND ANIMAL PRODUCTS
 
  CHAPTER I--ANIMAL AND PLANT HEALTH INSPECTION SERVICE, DEPARTMENT OF 
                               AGRICULTURE
 
PART 113--STANDARD REQUIREMENTS--Table of Contents
 
Sec. 113.34  Detection of hemagglutinating viruses.

    The test for detection of hemagglutinating viruses provided in this 
section shall be conducted when such a test is prescribed in an 
applicable Standard Requirement or in the filed Outline of Production 
for the product.
    (a) Final container samples of completed product rehydrated as 
recommended on the label shall be used as inoculum: Provided, That 
poultry vaccines distributed without diluent shall be rehydrated with 30 
ml of sterile distilled water per 1,000 doses and used as inoculum. When 
one or more fractions are to be used in combination with Newcastle 
Disease Vaccine, test samples shall be collected from bulk suspensions 
of each prior to mixing with the Newcastle Disease Vaccine.

[[Page 569]]

    (b) Each of ten 9- to 10-day-old embryonating eggs from Newcastle 
disease susceptible flocks shall be inoculated into the allantoic cavity 
with 0.2 ml of the undiluted inoculum.
    (1) Test five uninoculated embryos of the same age and from the same 
flock as those used for the test as negative controls.
    (2) Test an allantoic fluid sample of Newcastle disease virus as a 
positive control.
    (c) Three to five days post-inoculation, a sample of allantoic fluid 
from each egg shall be tested separately by a rapid plate test for 
hemagglutinating activity using a 0.5 percent suspension of fresh 
chicken red blood cells.
    (d) If the results are inconclusive, one or two blind passages shall 
be made using fluids from each of the original test eggs. Fluids from 
dead and live embryos may be pooled separately for inoculum in these 
passages.
    (e) If hemagglutinating activity attributable to the product is 
observed, the serial is unsatisfactory.

[38 FR 29889, Oct. 30, 1973]